Dexcom G6 Continuous Glucose Monitoring in Hemodialysis

a study on Diabetes Hemodialysis Glucose Measurement

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California
Dates
study started
estimated completion
Principal Investigator
by Connie Rhee, MD, MScKamyar Kalantar-Zadeh, MD, MPH, PhD

Description

Summary

This is a pilot study enrolling adult hemodialysis patients with diabetes recruited from the University of California Irvine Medical Center (UCIMC) who will undergo simultaneous measurement of glucose levels using 1) continuous glucose monitor (CGM) measured by a Dexcom G6 device vs. 2) "gold-standard" blood glucose levels using capillary fingerstick or venous blood glucose measurements obtained on a point of care (POC) blood glucose meter. The study will assess Dexcom G6 accuracy by comparing glucose levels on the CGM device vs. blood glucose measurements in the study population.

Official Title

Comparison of Dexcom G6 Continuous Glucose Monitoring System and Blood Glucose Levels in Adult Hemodialysis Patients With Diabetes

Keywords

Diabetes, Hemodialysis, Glucose Measurement, Dexcom G6 Continuous Glucose Monitor

Eligibility

You can join if…

Open to people ages 18 years and up

  • Adult hemodialysis patients age 18 years or older
  • Have a comorbidity of diabetes
  • Receipt of care from the inpatient University of California Irvine Medical Center nephrology consult service
  • Expected hospital stay ≥48 hours
  • Have the ability to directly provide informed consent for participation in the study

You CAN'T join if...

  • Critically-ill patients receiving care in the intensive care unit (ICU) or cardiac care unit (CCU)
  • Moribund patients expected to die within 48 hours
  • Presence of any condition deemed by PI's judgment that would seriously limit life expectancy (i.e., poor survival)
  • Pregnant
  • Unwilling or unable to provide informed consent

Location

  • University of California Irvine accepting new patients
    Orange California 92868 United States

Lead Scientists at UC Irvine

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT04217161
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated
Contact us about this trial